The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

Argos Therapeutics to Participate in 23rd Annual NewsMakers in the Biotech Industry Conference
Read more

Argos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
Read more

Argos Therapeutics to Host Second Quarter 2016 Financial Results Conference Call on Wednesday, August 10, 2016
Read more

> More News & Events >>>

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC